Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE? KIDNEY INTERNATIONAL Wyatt, C. M., Chertow, G. M. 2016; 90 (3): 460–65

Abstract

The recently published Heart Outcomes Prevention Evaluation trial (HOPE-3) demonstrated no benefit of lowering blood pressure with candesartan and hydrochlorothiazide in persons at intermediate cardiovascular risk and with adequate blood pressure control as determined by the enrolling physician. The results of Systolic Blood Pressure Intervention Trial (SPRINT) and HOPE-3 highlight the importance of considering differences in study design and patient population when interpreting the results of clinical trials.

View details for DOI 10.1016/j.kint.2016.06.021

View details for Web of Science ID 000382415300001

View details for PubMedID 27521103